Expanding the eligibility criteria for drugs in Canada's time-limited health technology assessment and temporary drug access processes will further accelerate access to new medicines

J Pharm Pharm Sci. 2024 Oct 8:27:13694. doi: 10.3389/jpps.2024.13694. eCollection 2024.
No abstract available

Keywords: health technology assessment; market access; novel medications; patients; reimbursement.

Publication types

  • Editorial